Letrozole

{

 "drug_name": "Letrozole",
 "FDA_approval": "Yes, for breast cancer; not FDA-approved for glioblastoma",
 "used_for": "Investigational use in glioblastoma based on preclinical studies",
 "clinical_trial_phase": "Preclinical studies and early research for glioblastoma",
 "common_side_effects": "Hot flashes, joint pain, nausea, fatigue, and risk of osteoporosis",
 "OS_with": "Not available; research in glioblastoma is still in early stages",
 "PFS_with": "Not available; research in glioblastoma is still in early stages",
 "usefulness_rating": "2 (based on early research potential, awaiting clinical trial outcomes for glioblastoma)",
 "toxicity_level": "2 (relatively low in the context of its approved use for breast cancer, with common manageable side effects)",
 "notes": "Letrozole, a drug commonly used in breast cancer treatment, has shown potential in preclinical studies for treating glioblastoma by targeting estrogen receptors, which are implicated in some glioblastoma cell growth. Further research, including clinical trials, is necessary to fully understand its efficacy and safety profile in glioblastoma patients.",
 "category": "Repurposed Drugs",
 "links": "https://braintomorrow.com/breast-cancer-drug-letrozole-glioblastoma/"

}